Explore the words cloud of the LYSADERM project. It provides you a very rough idea of what is the project "LYSADERM" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-05-01 to 2018-09-30|
Take a look of project's partnership.
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 with the aim of introducing into the market novel therapeutic products obtained from human Platelet Lysate. Episkey holds the exclusive licenses of international patents covering the therapeutic administration of cord blood Platelet Lysate, and already developed an international network of cord blood banks aimed at the procurement of Cord Blood Platelet Lysate for pharmaceutical transformation into platelet derivatives and drugs. Within the broad scope of our company mission, the LYSADERM project aims at marketing a novel formulation of dermatological cream containing tissue regenerative factors present in human platelets. The LYSADERM dermatological cream will be therefore used for the treatment of skin ulcers, including serious disorders, such as diabetic foot ulcers, pressure ulcers and leg ulcers. LYSADERM aims to be the first pharmaceutical cream containing Platelet Lysate, and it is expected to improve healing of the ulcers in comparison to conventional treatments, at lower cost; therefore, it would become the standard procedure to treat diabetic foot ulcers, pressure ulcers and leg ulcers. The LYSADERM business project is expected to generate positive outcomes for the whole society, such as the increase of effectiveness in the treatment of skin ulcers both in hospitals and at the patient’s home. It is roughly estimated that once industrialized, LYSADERM can generate in just 5 years a total of over 10 M annual revenues, covering the 0.4% of the EU market share. Overall, the main objective of our phase I project is to achieve the technical definition of the LYSADERM product, to realize a complete exploitation plan, and to consolidate our business plan through a second-level FTO and the definition of the financial forecasts.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYSADERM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LYSADERM" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
Carbon Offset Plug-inRead More
Interactive Digital Signage with emotional intelligence for smart citiesRead More